The largest CBD companies in the U.S. experienced declining market share in the second quarter, as the return of in-person shopping triggered a decline in e-commerce sales.
Market share by revenue for the top 20 CBD brands shrank 2 percentage points, to 16%, versus the first quarter of the year, according to Chicago-based cannabis analytics firm Brightfield Group.
British CBD maker Love Hemp Group was fined 100,000 pounds ($118,347) by the London-based Aquis Stock Exchange for misleading investors by announcing a capital raise of 2 million pounds that was not completed.
A California company specializing in hemp-derived delta-8 THC products has notched a fourth straight victory in copyright battles with competitors that it claimed were illegally using its protected brand.
A yearslong tailspin for CBD prices is showing signs of leveling off.
But it’s too soon to say whether the CBD market is rebounding or if companies making CBD products have simply cut so deeply that they’re now holding or increasing prices just to survive.
Marijuana customers around the world by and large shop based on one number: THC percentage.
Marijuana flower that doesn’t test above 20% THC often doesn’t make it on the shelf, and shoppers many times will pay a premium for flower that tests above 25% THC.
A group of federal health agencies have indicated in a government publication that they’d like to study various “minor cannabinoids” from marijuana, along with cannabis terpenes, to determine how they could best be used to treat a handful of medical ailments.
CBD is “safe and tolerable” in healthy adults and should be available without a prescription, a panel of scientists recommended to Canada’s top health regulator Thursday.
